Data from several tumour types indicate HDAC inhibitors increase MHC class I expression, counteracting the immune evasion undertaken by many cancers, as well as increasing chemokine expression and T-cell recruitment to the tumour [29–34]. This evidence concerns the gene HDAC9 and neoplasm.